Drug intelligence / Profile preview

CIM103

Development stage: Preclinical
Lead developer: CiMaas
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

**CIM103** is a preclinical CiMaas cancer-immunotherapy program for metastatic breast cancer that combines expanded donor-derived NK-Xpand natural killer cells with an anti-TROP2 monoclonal antibody. The anti-TROP2 antibody is intended to bind trophoblast cell-surface antigen 2 on tumor cells, while the NK-cell component mediates tumor-cell killing, including antibody-dependent cellular cytotoxicity through NK-cell Fc receptor engagement.

Targets

FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on CIM103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIM103.

Explore the full profile